Maxim Group Upgrades Co-Diagnostics (CODX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CODX Hot Sheet
Price: $0.36 -5.26%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Co-Diagnostics (NASDAQ: CODX) from Hold to Buy.
For an analyst ratings summary and ratings history on Co-Diagnostics click here. For more ratings news on Co-Diagnostics click here.
Shares of Co-Diagnostics closed at $18.85 yesterday.
You May Also Be Interested In
- Co-Diagnostics (CODX) files for 39.6M share offering by selling stockholders
- CFRA Upgrades Nucor (NUE) to Hold
- JPMorgan Upgrades Meitu Inc (1357:HK) (MEIUY) to Overweight
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
